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1. Introduction
Few species of butterflies and moths (order Lepidoptera) are involved in human envenoming
[1]. Caterpillars are the larval forms of moths and butterflies. Toxins are usually found in the
caterpillar’s hairs and spines with defense purposes. The majority of medically important
encounters with lepidopterans occur with exposure to the caterpillar’s urticating hairs or
spines, but hemolymph can also have toxic properties [1, 2]. A variety of clinical effects have
been described, which depend on the family and species involved, ranging from local to
systemic reactions [3, 4].
In most occasions, the adverse effects caused by caterpillars are self-limited and can be treated
with topical antipruritics [4]. However, for the envenoming by the South American Lonomia
obliqua caterpillars (Figure 1), named lonomism, the antilonomic serum produced at the
Butantan Institute in Brazil is the only effective treatment to reestablish the coagulation
parameters in poisoned patients and to avoid the complications seen in severe cases such as
intracerebral hemorrhage and acute renal failure [5-10].
In 1989, an outbreak of accidents with this species became a serious public health threat in
southern Brazil, with high fatality rates [5, 11-15]. Since then, many studies have been carried
out to understand the pathophysiological mechanisms of envenoming [14] and to identify the
toxins responsible for adverse reactions.
© 2013 Chudzinski-Tavassi et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. A) Lonomia obliqua caterpillar (5th instar) and B) pupa.
L. obliqua is the caterpillar that has the most studied venom, which main components have
been isolated and characterized [14, 16, 17]. Table 1 lists the biological activities and toxins
isolated and characterized from the bristle extract or hemolymph of L. obliqua. In vivo studies
reported an antithrombotic effect caused by the bristle extract, while most in vitro studies
reported procoagulant activities [14, 16-23]. It is well known, for a wide range of animal
venoms, that procoagulant toxins can cause in vivo activation of the coagulation system. The
hemostatic disturbances observed in the envenoming by L. obliqua caterpillars, result in a
consumption coagulopathy (resembling a disseminated intravascular coagulation) and
secondary fibrinolysis, which can lead to the hemorrhagic syndrome [6].
The principal components in the caterpillar’s venom have been initially identified by isolating
toxins through classical purification methods and following the main activities observed in
the whole bristle extract (Figure 2). However, this approach provides knowledge restricted
only to the most abundant toxins, and usually reveals that activities which are directly
associated to the main symptoms and effects observed in the envenoming outcomes. Experi‐
mental assays were specifically developed to test the hemostatic and enzymatic activities of
Lonomia toxins and their actions on the coagulation cascade. This knowledge has been valuable
for description and management of the envenoming syndrome, but with the classical ap‐
proach, low abundant components and unexpected effects are usually overlooked. Possible
interaction of venom components, cross-reactions and secondary effects, useful to provide a
systemic view of the pathways involved in the toxin’s effects are often unnoticed.
In the last years, methods applied in genomic, transcriptomic and proteomic analyses have
been applied with the aims of cataloging and classifying the toxins based on their structure
and activity (Figure 3). Thus, it was possible to analyze the envenoming processes at the
molecular level. For example, significant advance was achieved through two independent
transcriptome studies, which generated a list of putative toxic proteins from L. obliqua bristles
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and hemolymph [20, 43]. In addition, significant advance was achieved as a result of micro‐
array study [44]. Moreover, by coupling proteomics and immunochemical approaches, some
immunogenic components were identifying in the bristle extract, especially those related to
hemostasis [9]. These components were detected by the antilonomic hyperimmune serum
produced at the Butantan Institute, and abundant proteins were identified.
Activity
(toxin)
Source MW (kDa) Characteristics and observed effects Reference
Prothrombin
activation (Lopap)
Bristle extract 21 Serine protease, activity increased by Ca2+;
consumption coagulopathy in vivo; cell survival
in endothelial cell culture. Recombinant form
produced in bacteria and yeast.
[18, 19, 21,
24-26]
FXa-like Bristle extract 21 Hydrolytic activity on S-2222 chromogenic
substrate, Ca2+-independent; N-terminal
sequence similar to Lopap.
[27]
Factor X activation
(Losac)
Bristle extract 45 Serine protease, Ca2+-independent;
Cell survival in HUVEC. Recombinant form
produced in bacteria.
[20-22, 28]
Phospholipase A2-like Bristle extract 15 Indirect hemolytic activity in human and rat red
blood cells in vitro, Ca2+-independent;
intravascular hemolysis in vivo.
[29-31]
Fibrinogenolytic
(Lonofibrase)
Hemolymph 35 αβ fibrinogenase activity; enable to affect fibrin
cross-linked.
[32-34]
Hyaluronidase
(Lonoglyases)
Bristle extract 49
53
β-endohexosaminidase activity; degradation of
extracellular matrix.
[35]
Antiapoptotic Hemolymph 51 Activity on Spodoptera frugiperda (Sf-9) cell
culture.
[36]
Antiviral Hemolymph 20 Antiviral activity against measles, influenza and
polio viruses. Recombinant form produced in
baculovirus/insect.
[37, 38]
Nociceptive and
Edematogenic
Bristle extract NI Nociception facilitated by prostaglandin
production; edematogenic response facilitated
by prostanoids and histamine.
[39]
Kallikrein-kinin
system activation
Bristle extract NI Kinin release from low molecular weight
kininogen; edema formation and fall in arterial
pressure.
[40]
Platelet adhesion and
aggregation
Bristle extract NI Direct platelet aggregation and ATP secretion;
activity inhibited by p-bromophenacyl
bromide, a specific PLA2 inhibitor.
[41, 42]
NI: None isolated, studies carried out using the whole venom
Table 1. Toxins and activities described in L. obliqua venom.
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Figure 2. Schematic representation of the classical strategy employed in initial studies of the Lonomia obliqua venom.
The bristle extract was analyzed through denaturing electrophoresis (SDS-PAGE) which showed the venom is a com‐
plex mixture of proteins. Screening assays were carried out to investigate possible effects on blood coagulation and
fibrinolysis. The venom showed procoagulant activity by decreasing blood clotting time. Two procoagulant compo‐
nents (Lopap, a prothrombin activator and Losac, a factor X activator) were identified and isolated from the bristle
extract for further characterization. The specific activity of Lopap and Losac were observed on purified coagulation
factor zymogens (FII or FX) using chromogenic substrates to detect generation of active forms of clotting factors (FIIa
and FXa) by these toxins. This assay was used in the purification process to identify the active fractions containing each
toxin. SDS-PAGE profile shows Lopap (1- multimer, 3- monomer) and Losac (2) are abundant components in the ven‐
om. MM: molecular markers.
Production of recombinant forms of Lonomia toxins and discovery of new molecules are
opening perspectives in the scientific area for basic and applied researches. These molecules
can point out novel mechanisms of action, undiscovered molecular interactions and new
classes of enzymes and inhibitors. Interesting, some venom toxins have shown multifunctional
properties [19, 22, 28]. The best examples are Lopap (a prothrombin activator with high
similarity with lipocalins) and Losac (a factor X activator highly similar to hemolins). Besides
activation of blood coagulation, Lopap and Losac can modulate cellular functions and promote
cell survival [22, 45]. Both molecules were cloned and produced in its recombinant form in
yeast and/or bacteria [19, 25, 28].
Additional studies will be conducted to determine the involvement of the venom components
in the envenoming syndrome and their biological significance for physiological processes of
the animal, such as insect metamorphosis, which is a combination of growth/activation/
differentiation/programmed cell death signals. Thus, this chapter reviews the currently
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available information about L. obliqua venom, and focus on strategies to unveil molecular
aspects of toxins and the perspectives for therapeutic and biotechnological applications.
Figure 3. Schematic representation of the strategies to explore the Lonomia obliqua venom and toxins based on cel‐
lular and molecular approaches. Results obtained indicate promising applications for these proteins and derived pep‐
tides.
2. Molecular approach
For many years, direct purification of toxins from venoms was the best procedure to charac‐
terize them with regard to their primary structure. Then, the development of molecular
approaches to characterize toxin genes represented an expansion in the understanding of the
structure and function of toxin, critical for the development of new treatments directed against
the venom toxins (antivenoms). Cloning of cDNAs coding for biochemically isolated toxins
has improved their characterization. Transcriptomic allows the identification of cellular
transcripts in a given cell population, while proteomic studies protein’s properties and
functions (expression level, structure, post-translational modification, etc.) of proteins
expressed by the genome of an organism at a certain point of time. The availability of tech‐
nologies for high throughput analysis has led to integrate toxin expression at mRNA and
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protein level. This flow of genetic information from DNA to proteins is the base of the central
dogma of molecular biology [46].
2.1. Transcriptomics of Lonomia obliqua bristle extract
Expressed Sequence Tags strategy is an approach to characterize the transcriptome of a cell,
gland or organism and is based in all the transcript (the most abundant are the mRNAs)
produced at a specific time and fully sequenced to create a representative catalogue of
expressed genes [47]. Hundreds to a thousand of sequences are grouped into contigs or clusters
based on DNA sequence information and bioinformatics analysis (Figure 4). Nowadays, the
EST-based strategy is commonly employed for identifying expressed genes in species of
interest [48, 49]. This approach has been successfully used to compile a lists of genes expressed
in venom’s glands of a wide range of animals [50-53].
EST-strategy was used to identify the major transcripts present in L. obliqua bristle extract [19,
20, 43]. About 702 clusters (representing 1,278 independent clones) were assembled and
characterized as lipocalins, hemolins, serine proteases, serine protease inhibitors, serpins,
tumor suppressors, ribosomal, structural and cell cycle proteins as shown in Table 2 [20]. Most
of the transcripts represent proteins involved in the animal physiology. Those sequences were
deposited in data bank (NCBI GenBank accession numbers: CX815710–CX817210, CX820335–
CX820336, AY908986) [20]. A pool of DNA sequences showed no similarities with well-known
sequences in data bank. The most abundant toxin was a lipocalin of 21 kDa, and analysis of its
N-terminal sequence shows 100% homology with Lopap (GenPept accession number:
AAW88441). The Lopap whole sequence (accounting for 1.6% of the total clones) was identified
in this cDNA library (accession number: AY908986).
Functional categories No. ofclusters No. of clones
Clones/
clusters % of Total % of Hits
General Metabolism 72 94 1.30 6.1 7.0
Transcriptional and translational 165 462 2.80 30.7 37.0
Processing and sorting 10 13 1.30 0.8 1.0
Degradation 9 20 2.22 1.3 2.0
Structural functions 47 243 5.17 16.2 19.0
Cell regulation 26 82 3.15 5.4 6.0
Other functions 138 244 1.77 16.2 19.0
Conserved unknown proteins 42 120 2.86 8.0 9.0
TOTAL 509 1278 2.51 85.0 100.0
Table 2. Major transcripts present in the Lonomia obliqua bristle extract identified by EST-based strategy. Adapted
from EST data-bank of NCBI deposited by Reis and colleagues in 2004 [19, 20].
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Other cDNA libraries were constructed from bristles and integument [43]. The transcripts of
those libraries revealed the presence of sequences related to trypsin-like enzymes, blood
coagulation factors, prophenoloxidase cascade activators, cysteine proteases, phospholipase
A2, serpins, cystatins, antibacterial proteins, lipocalins, and others (GenBank accession
number: AY829732–AY829859) [43]. Sequences deposited independently in gene banks from
both cDNA libraries are complementary. Apart from new venom component precursors, both
Figure 4. Schematic view of a transcriptomic approach based on EST-strategy. The strategy of construction of the
cDNA library starts by the extraction of total RNA from a sample (ex. L. obliqua bristle extract). After purification of the
mRNAs with an oligo (dT)-cellulose column, the cDNAs are synthesized (reverse transcription) by using synthetic oligo‐
nucleotides containing a restriction sites (in figure: NcoI and EcoRI for sense and antisense primers, respectively). The
cDNA obtained can be inserted into a vector (plasmids or phages), generating a cDNA library. The library can be per‐
petuated by transforming the clones (plasmids) or infecting themselves (in the cases of phages) in E. coli. Based on
DNA sequence information, bioinformatics tools predict the amino acid sequence of the corresponding gene products
and their similarity to known genes. The redundant EST data sets are organized and integrated into cluster [54, 55].
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libraries describe gene products related to cellular processes important for venom production,
including high protein synthesis, tuned post-translational processing and trafficking. Those
important projects contributed significantly to the characterization of this venom, which
showed to be a rich source of proteins and active principles. Further studies about the biological
and pharmacological properties of these molecules are necessary to understand its involve‐
ment in the envenoming process. Recently, the next-generation of sequencing methods - for
example, pyrosequencing - have improved and increased the sequencing reducing time and
cost compared to the traditional Sanger method [47, 56].
2.2. Microarray analysis
The identification of genes expressed in cells of a tissue is a basic step to provide essential
information about gene function and tissue physiology. The gene expression analysis through
the microarray technology (cDNA arrays) has become a powerful tool for rapid analysis of the
functional effects of toxins on cells and tissues [57]. The main application of cDNA arrays is to
compare the expression of known genes in different physiological situations, for example,
tissues in normal and pathological conditions [58]. Thus, analyses of array data contribute to
a better understanding of complex gene expression patterns related to physiology and
metabolism, unveiling networks or pathways previously unknown.
A study of the effects of L. obliqua bristle extract on the gene expression profile of cultured
human fibroblasts showed that many genes are up- and down-regulated, especially those
related to the inflammatory processes such as IL-8, IL-6, CXCL1 and CCL2 [44]. Other changes
in the expression pattern of some genes, such as prostaglandin-endoperoxide synthase 2,
urokinase-type plasminogen activator receptor and tissue factor, were also observed, which
could contribute to the pathological effects of lonomism. The authors suggest that the clinical
manifestations may be a result of the direct action of L. obliqua venom on the host cells allied
to an indirect effect caused by alteration in the gene expression pattern in host tissues.
2.3. Immunoproteome of Lonomia obliqua bristle extract
The identification of antigens eliciting an immune response by applying proteomic technolo‐
gies can be defined as Immunoproteomics. Some usual immunoproteomics approaches are
shown in Figure 5. Here, the perspective for its application regards the improvement of serum
therapy by the selection of antigens for toxin-specific immunization of horses. Furthermore,
some applications correlate the identification of antigens with certain diseases, such as
infectious, autoimmune or cancer, providing diagnostic and monitoring informations. In this
way, these methodologies are good choices in developing clinical applications and also to
discover biomarkers. [59].
In classical gel-based strategy, the isolation and identification of proteins/antigens comprises
a combination of bidimensional electrophoresis, immunoblotting and mass spectrometry. The
aim of bidimensional electrophoresis is to isolate proteins based on their charge and mass [60,
61]. The first step is isoelectric focusing (IEF), where proteins migrate to reach their isoelectric
point in an immobilized pH gradient gel under high voltage. All proteins are given negative
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charge by addition of SDS detergent. This step also includes denaturation of proteins by
reduction and alkylation. The second step is SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), where smaller proteins migrate faster through the gel to the anode than larger ones.
Detection of proteins can be performed by gel staining or immunoblotting.
Immunoblotting involves the transfer of proteins from gel to a nitrocellulose or PVDF
membrane in an electric field [62]. The immobilized proteins in the membrane are subsequently
incubated with antibodies that have affinity for the proteins of interest. Detection is carried
out by enzyme-labelled secondary antibodies against the constant region of the primary IgG
antibody, followed by the addition of a chemilluminescent substrate. The substrate reaction
can be visualized by fluorescence.
Figure 5. General approaches in Immunoproteomics. Gel-based approach: Bidimensional electrophoresis is based on
protein separation on their pI and molecular mass. Then, the proteins are transferred from gel and immobilized on
membrane (Western blotting). Antigens will be detected after serum incubation, followed by addition of secondary
labelled antibodies and their substrates. Gel-free approaches: Antigen array: Proteins are fractionated (pI, hydropho‐
bicity,etc) and spotted in a solid support. After that, antigenic fractions can be detected using patient serum and sec‐
ondary labelled antibodies. Antigen profiling: Immunocapture is based on immobilization of patient
immunoglobulins G, which are directly used to capture and isolate antigenic proteins from a complex mixture of pro‐
teins. Captured antigens are profiled by mass spectrometry (modified from 66).
Following this, the immunogenic proteins are removed from the gel and enzymatically
digested for further mass spectrometry analyses [63]. Trypsin is generally used, cleaving an
amide bond on the C-terminal side of lysine and arginine residues, which will be protonated
and analyzed in positive-ion mode. Addition of diluted acid (0.1% formic acid or 1% trifluor‐
acetic acid) to the sample contributes to the ionization process.
The ionization methods that are most often used for peptides and proteins are Matrix Assisted
Laser Desorption Ionization (MALDI) and Electrospray Ionization (ESI). Peptides and proteins
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can be identified by Peptide mass fingerprinting (PMF) or de novo sequencing [63]. PMF is
based on their fragmentation pattern, considering that identical peptide maps have identical
amino acid sequences. For de novo sequencing analyses, the precursor ion is selected for
fragmentation and the product ions are evaluated by mass differences between successive
peaks in the spectrum, which are related to the individual mass of their residues.
The identification of immunogenic compounds from L. obliqua’s bristle extract was performed
on gel-based approach using the polyclonal horse anti-Lonomic hyperimmune serum and anti-
Lopap specific rabbit serum produced by the Butantan Institute [9]. Bidimensional electro‐
phoresis of bristle extract revealed 157 silver stained spots, under non-reducing conditions
(without DTT and iodoacetamide addition), providing an overview protein mapping (Figure
6A). However, 153 spots were immunodetected using anti-Lonomic serum (Figure 6B) and 30
spots detected using anti-Lopap serum (Figure 6C). Abundant proteins from 24 selected
colloidal Coomassie Blue gel spots, corresponding to immunogenic proteins, were digested
with trypsin and analysed by tandem mass spectrometry. The identification searches were
carried out using the L. obliqua bristle EST databank. Lipocalins (spots 05, 09, 10, 14, 15, 16, 18,
24), cuticle protein (spots 05, 06, 07, 08, 11, 12, 13) and serpins (spot 21) were amongst the
proteins identified (Figure 6A) [9]. Lipocalins can play a role in homeostasis and inflammation,
as a defense mechanism in haematophagous arthropods. Lopap, characterized as a lipocalin
protein member, and its all isoforms were highly represented as immunogenic proteins,
revealed by the specific anti-Lopap serum (Figure 6C). The bristle’ cDNA libraries also confirm
the high abundance of lipocalins. As previously described [9, 19], these proteins have impor‐
tant role in envenoming. The cuticle proteins identified can be related to the inflammatory
response caused by macerated spicule proteins. The serpin protein may also be involved in
the defense mechanism.
Besides the biochemical and pharmacological tests, the quality control of serum and vaccine
production can be monitored by proteomic technologies [64], such as chromatographic
analyses, bidimensional electrophoresis and immunoblotting, once they are able to detect
protein degradation and also confirm the presence of specific antibodies. However, immuno‐
therapy can be more effective if a better characterization of venom composition is performed,
improving immunization procedures, increasing its specificity and reducing side effects. The
new generation of high affinity antibodies against low abundant immunogenic toxins can be
evaluated by an antivenomic approach [64, 65].
A novel approach is the investigation of post-translational modifications (PTM) that affect
antigen recognition, given that many peptides presented to T cells by the major histocompa‐
bility complex are post-translationally modified [66]. Glycosylation and phosphorylation are
important PTMs of proteins, playing crucial roles in several biological processes, including
cell recognition and signalling pathway [67, 68]. Some potential targets for cancer therapy are
based on glycosylated and phosphorylated epitopes discoveries [59].
Otherwise, phosphorylated proteins are usually enriched by immunoprecipitation (mainly for
phosphotyrosine peptides) or by chromatographic procedures, such as Strong Cation eX‐
change (SCX), Hydrophilic Interaction Liquid Chromatography (HILIC), Immobilized Metal
Affinity Chromatography (IMAC) or Metal Oxide Affinity Chromatography (MOAC).
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Figure  6.  Bidimensional  electrophoresis  and  immunoblotting  from  Lonomia  obliqua’s  bristle  extract.  (A):  silver
stained bidimensional gel (100 μg of protein applied) under non-reducing condition. Panels (B) and (C): PVDF im‐
munoblotted 2D gels incubated with anti-Lonomic horse serum diluted 1:500 (B) or with anti-Lopap rabbit serum
diluted 1:250 (C) [9].
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Different metals may be used (iron, zirconium, gallium, etc) and peptides eluted by acidic or
basic conditions, releasing mono-phosphorylated and multi-phosphorylated peptides,
respectively [67].
The simultaneous screening of thousands of proteins from complex samples in a fast and
sensitive manner can be performed using protein arrays. Amongst the different protein
microarray applications are biomarker discovery, protein interaction studies, enzyme-
substrate profiling, immunological profiling and vaccine development. As our interest is in
the immune response, an antibody microarray can be used for identification of antigens that
react specifically with the antibodies spotted on a solid support, with the complex formed then
detected by fluorescence [59].
A large number of not yet identified proteins are considered as unknowns, but higher
probabilities of identifications are reached when different methodologies are applied for
analysis of complex samples. The combination of several proteomic techniques described here
could improve the detection of immunogenic compounds and create new perspectives for
effective immunotherapies.
3. Lonomia obliqua toxins
The L. obliqua caterpillar venom contain non-protein and protein components [21]. The
procoagulant proteins present in the venom cause hemostatic disturbances mainly mediated
by thrombin formation, the key enzyme of blood coagulation. Physiologically, thrombin
generation from prothrombin occurs by assembling of the prothrombinase complex, which
consists of factor Xa (catalytic factor), factor Va (non-enzymatic cofactor), calcium and a
phospholipid membrane surface. Despite figured as a cascade of subsequent activation of
coagulation factors, blood coagulation is currently conceived in a cell based-model [69]. In
Figure 7 a simplified cascade model of hemostasis is illustrated, showing the known interac‐
tions of the L. obliqua venom and toxins.
Several molecules and activities were reported in bristles or hemolymph (Table 1). Some of
them are related to the pathophysiology of the envenoming others to the development process
of the animal such as regulation of the cell cycle [16]. Donato and colleagues [70] identified in
the bristle extract a direct factor X activator which is calcium-independent, and a prothrombin
activator. The prothrombin and factor X activators were later isolated and named Lopap and
Losac, respectively [22, 24]. Interestingly, both molecules are no longer similar with any well-
known procoagulant molecule from human or any other species.
3.1. Lopap: Functional characterization, recombinant production and bioinformatics
analysis
Lopap (Lonomia obliqua Prothrombin Activator Protease) was purified from the bristle extract
as a 69-kDa protein through gel filtration followed by reverse-phase chromatography. The
purified protein was subjected to trypsin hydrolysis and partial amino acid sequences of N-
terminal and internal fragments were obtained through Edman degradation [24].
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The recombinant protein (rLopap) was obtained in enzymatically active form as monomer of
21 kDa with a polyhistidine tag after purification by immobilized metal-chelate affinity
chromatography. Partial amino acid sequences of native Lopap lead to identification of its
respective clone from the cDNA library of L. obliqua bristles [20], encoding for a signal peptide
(16 aa residues) and the mature protein (185 aa residues). cDNA of mature protein, consisting
in a transcript with 603 bp open reading frame, was subcloned into the pAE vector and
expressed in the bacteria E. coli BL21(DE3) with a fusion tag (His6). Protein was recovered in
inclusion bodies after cell lysis and subjected to refolding and purification after solubilization
in urea [71].
Interestingly, the deduced amino acid sequence of Lopap showed no similarity with other
prothrombin activators or serine proteases, but was similar to lipocalin family members, either
from insects or mammals [71]. Lopap sequence alignment with other lipocalins is shown in
Figure 8. Members of lipocalin family usually share only about 30% of similarity in amino acid
Figure 7. Schematic overview of hemostasis. Dark double-bars indicate where inhibitors act. HMWK = high molecular-
weight-kininogen. PK = Prekallikrein. KK = Kallikrein. CI-INH = CI-inhibitor. TFPI = tissue factor pathway inhibitor. PL =
phospholipids. Ca = calcium ions. AT = antithrombin. FDA = Fibrinopeptide A. FDB = Fibrinopeptide B. TAFI = Throm‐
bin-activatable fibrinolysis inhibitor. FnDP = Fibrin degradation products. FgDP = Fibrinogen degradation products. α2-
AP = α2-antiplasmin. Known interactions of the L. obliqua venom are indicated in the black boxes. Losac = L. obliqua
Stuart factor activator. Lopap = L. obliqua prothrombin activator protease.
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sequence, despite showing conserved secondary and tertiary structures. Furthermore, these
proteins have in primary structure three characteristic conserved motifs [72].
Figure 8. Amino acid sequence alignment of Lopap and other lipocalins. Sequences were accessed from protein data
bank at NCBI and aligned using BioEdit [80].
Lopap’s tridimensional structure obtained by molecular modeling has the characteristic fold
of lipocalins, consisting in an eight stranded antiparallel β-barrel (Figure 9) with a hydrophobic
pocket for binding of hydrophobic ligands. A serine protease catalytic triad was also predicted
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[19]. Lopap is the first lipocalin described that displays proteolytic activity. On the other hand,
through a peptide mapping approach based on lipocalin conserved motifs found in the
Lopap’s primary structure, a synthetic peptide was obtained (Figure 10), which has been
proposed as a sequence signature among lipocalins, sharing a common role in cell protection
and development process [73]. Other lipocalins that have been described with antiapoptotic
activity share similar sequences, which have similar conformations in their tridimensional
structures [73].
Figure 9. Model of the tridimensional structure of Lopap [81].
Figure 10. Lipocalin sequence signature highlighted among lipocalin conserved motifs identified in Lopap sequence
[19] and in the model of tridimensional structure. Residues predicted in the catalytic triad are shown in green [25].
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Lopap shows specific proteolytic activity towards prothrombin. It displays serine protease-
like activity and activates human prothrombin through hydrolysis of Arg284-Thr285 and Arg320-
Ile321 peptide bounds, generating active thrombin, without formation of the intermediate
meizothrombin [24]. This mechanism is similar to prothrombin activation by FXa in absence
of the prothrombinase complex (Figure 11), previously described [74]. This is the unique
prothrombin activation mechanism described for an exogenous serine protease, which is
independent of prothrombinase complex components. All other exogenous prothrombin
activators (metalloproteases and serine proteases) currently described from snake venoms fit
into four groups, sharing similar mechanisms of action [75].
Figure 11. Prothrombin activation mechanisms indicating the Lopap hydrolysis sites and its generated products.
When administered in vivo, Lopap induces blood clotting into microvessels, resulting in
fibrinogen consumption and blood incoagulability [76]. These effects resemble the consump‐
tion coagulopathy triggered by the whole venom, indicating the involvement of this pro‐
thrombin activator as a key toxin in envenoming [26]. In addition, Lopap is able to modulate
endothelial cell responses promoting cell survival, IL-8, nitric oxide (NO) and PGI2 release,
expression of the cell adhesion molecules ICAM-1 and E-selectin, but not VCAM-1 and
PCAM-1 [45, 77, 78]. Lopap also displays cytoprotective activity in neuthrophils and do not
modify expressions of L-selectin and β2 integrin. Secretion of the proinflammatory cytokines
IL-6 and TNF-α is not changed by Lopap treatment in both cell cultures [78]. Lopap seems to
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have no effect on modulation of coagulation and fibrinolysis through endothelial cell response,
since it does not modify von Willebrand factor (vWF) and tissue plasminogen activator (t-PA)
release or tissue factor procoagulant activity on endothelial cell surface [45, 77].
The Lopap-derived peptide obtained through chemical synthesis (Survicalin) reproduces the
Lopap’s modulation on endothelial cells and neutrophils cell, triggering antiapoptotic activity
[73]. Survicalin also induces fibroblast responses, decreasing caspase-3 and increasing Bcl-2,
Ki-67, IL-1β and the receptors for IL-8 and IL-6. Enhanced production of extracellular matrix
proteins, such as collagen, fibronectin, tenascin and laminin is also induced by Survicalin in
fibroblast culture [79].
3.2. Losac: Functional characterization
Losac is the first factor X activator purified from a lepidopter secretion. It was obtained from
caterpillar’s bristle extract as a single polypeptide chain protein of about 45 kDa [22]. Some
years later, from a cDNA library of L. obliqua bristle transcripts [19], the specific clone encoding
for Losac was identified and the recombinant protein produced in bacteria system (for details,
see section 3.3). Studies using the native or recombinant form of Losac (rLosac) revealed
specificity toward factor X [20, 22, 28]. Moreover, Losac had no effect on fibrin or fibrinogen,
indicating its specificity for blood coagulation activation, and it was recognized by the
antilonomic serum produced in Butantan Institute. Thus, it is plausible that this protein
participates in the consumption coagulopathy observed in patients.
Biochemical characterization of Losac has shown that, although its sequence did not show an
equivalent among other factor X activators, Losac possess a similar mechanism of action than
RVV-X, a factor X activator purified from Russell’s viper venom Daboia russelli [28, 82, 83]. Like
RVV-X, factor X activation by Losac can be accelerated in the presence of calcium and phos‐
pholipids, two important cofactor in the assembling of blood coagulation complexes [69]. In
spite of this, Losac can activate factor X independently of these cofactors. Moreover, both
activators require a stable conformation of factor X and the presence of the Gla-domain of
factor X for an appropriated activity. Interestingly, the cleavage fragments of factor X gener‐
ated by both activators were quite similar. Although there are strong functional similarities,
the major difference is in the structure of both activators. Apparently, Losac activates factor X
through a serine protease-like activity, while RVV-X has a typical metalloproteinase structure
[20, 28, 84].
A model proposed by Morita [83] and crystallographic studies of RVV-X [85] support the
hypothesis that it primarily recognizes the calcium-bound conformation of Gla-domain in
factor X through an exosite formed by the light chains, followed by the catalytic conversion of
factor X to factor Xa. Despite the structural differences between Losac and RVV-X, it remains
possible that they share a similar mechanisms for recognition of factor X involving calcium
ions, phospholipids and the Gla-domain of factor X followed by its proteolytic conversion to
active factor X.
Besides its role in coagulation [22, 28], Losac is also capable of inducing proliferation and
inhibiting endothelial cell death while stimulating the release of NO, a known molecule with
Toxins from Lonomia obliqua — Recombinant Production and Molecular Approach
http://dx.doi.org/10.5772/53697
191
antiapoptotic activity [86, 87], and t-PA, a component of fibrinolytic-pathway involved in
matrix remodeling [88]. The authors suggest that the cell proliferation and cell viability
activities elicited by Losac are probably related to the NO liberation [22], since NO was also
described as an endothelial survival factor, inhibiting apoptosis [86, 87]. Moreover, it was also
observed that the production/expression of some important molecules involved in inflamma‐
tion and coagulation systems such as ICAM-1, PGI2, DAF, IL-8, vWF and tissue factor were
not affected by Losac.
It has been show that hemolymph from some insects can increase cell longevity by inhibiting
apoptosis [89, 90]. The increase of Spodoptera frugiperda Sf-9 cell growth in almost 3-fold was
reported after supplementation with L. obliqua hemolymph [91]. This effect was attributed to
the presence of three factors with different activities: a potential antiapoptotic factor, a growth-
promoting factor, and an enzyme that hydrolyzes sucrose. Furthermore, an antiapoptotic
protein of 51 kDa was purified from L. obliqua hemolymph [36]. This protein was able to prevent
apoptosis in Sf-9 cell culture induced by nutrient deprivation and by Actinomycin D. Later
reports [37, 38] described in the hemolymph a potent antiviral activity against human virus.
3.3. Molecular cloning and heterologous expression of Losac
The production of Losac in a recombinant form was important due to the disadvantages of
purifying Losac from bristle extract: the use of many caterpillars to prepare the bristle extract
and the low yield of native Losac (0.3%) [22]. Cloning and production scheme to obtain rLosac
is shown in Figure 12 [28].
Nucleotide and deduced amino acid sequences were compared with data banks in order to
identify similar genes and their products. The analysis revealed a high similarity with members
of the immunoglobulin-like superfamily of cell adhesion molecules (IgCAMs), especially with
neural CAMs (NCAMs) [28]. Members of this group have diverse functions but none was
associated with proteolytic activities [94]. Multiple comparison of the deduced amino acid
sequence revealed different degrees of identity with IgCAMs: 26% of identity with L1-NCAM
from humans, 34% with the protein neuroglian from Drosofila melanogaster; and 47-76% with
hemolins from lepidopters [95-98]. Although no structural data was reported for Losac, a
tertiary structure model was built through homology modeling based on crystal structure of
Hyalophora cecropia hemolin (HcHemolin, Protein Data Bank code 1BIH). Both proteins share
76% of sequence identity [28] and the same multi-domain structure (four Ig-like domains: D1
to D4) and conserved motifs as shown in Figures 13 and 14. Both structures are composed of
β-strands, arranged in a globular shape resembling a horseshoe (Figure 14A), akin to hemolin
[97], axonin [99], and the four N-terminal Ig domains of neurofascin [100]. Because Losac shares
its main sequence features with hemolins, it can be perfectly classified as one of them. It was
demonstrated that Losac activate factor X in a similar way than RVV-X [28]. Nevertheless,
unlike Losac, no hemolins or cell adhesion molecules were associated with proteolytic
activities.
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Figure 12. 1)After purification from bristle extract [22], Losac was submitted to a tryptic digestion to obtain partial
amino acid sequences of internal fragments. Those sequences were obtained by mass spectrometry and used to
screen the cDNA library to identify the transcript encoding the protein. The cDNA library was previously constructed
with L. obliqua bristle mRNAs that were converted to cDNA and cloned into pGEM-11Zf+ plasmid [19, 20]. 2) From this
cDNA library, a transcript corresponding to the clone LOAH12B08 (GenBankTM accession number CX816408.1),
matching the tryptic peptide sequences, was identified. However, this transcript was partially sequenced and the com‐
plete sequence was achieved through the primer walking strategy using a specific primer designed from an internal
sequence of the transcript allowing uncover the complete sequence of Losac gene [92]. The nucleotide sequence has
been deposited in GenBankTM (DQ479435), and the deduced protein has been deposited in the NCBI protein se‐
quence database (ABF21073). 3) The cDNA that encodes mature Losac was amplified by PCR using a sense and an
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antisense primer designed according to the deduced N- and C-terminal sequences of the mature protein carrying NcoI
or EcoRI restriction sites, respectively. 4) The cDNA corresponding to mature Losac was sub-cloned into the pAE vector
[93]. The PCR product and the pAE vector were restricted with NcoI and EcoRI, purified, and ligated with T4 DNA ligase
and used to transform E. coli DH5α cells. 5) The resulting pAE-Losac plasmid was used to transform E. coli BL21(DE3)
cells. The recombinant protein was expressed in fusion to a minimal N-terminal His6-tag as a 48.6 kDa protein: Protein
was recovered in inclusion bodies after cell lysis and subjected to refolding and purification after solubilization in urea.
Figure 13. Multiple amino acid sequence alignment of Losac with other hemolin proteins. Sequence identity is shown
for all proteins related to Losac. The structures encompass four constant-type immunoglobulin domains (cIg) (D1-D4).
The bars above the sequences correspond to domains 1 (D1, blue), 2 (D2, green), 3 (D3, orange) and 4 (D4, red). Se‐
quence identity is shown for all hemolins related to Losac (%ID). The α-helices and β-sheets observed in Hyalophora
cecropia hemolin (Protein Data Bank code 1BIH) and Losac are shaded in light and dark gray, respectively. Previously it
was predicted that hemolin contain conserved regions and motifs (28, 36). Conserved motifs are shown inside boxes
according to the domain they belong. The eight cysteines (in yellow) form four intra-chain disulfide bridges. Losac
conserves the well-known motifs involved in cell-adhesion mechanism (KDG motif in D1 and D3), as well as the highly
conserved N-glycosylation site in D3 (Asn265, in black). An additional N-glycosylation site (Asn22) is found in H. cecropia
and S. c. ricini hemolins (D1). The LPS-binding site (NRTS motif: Asn265, Arg266, Thr267 and Ser268) in D3 (orange). In D2
are located the KRLS cAMP/cGMP-dependent protein kinase phosphorylation site and the RRIT motif (green boxes).
Positions of the residues forming the putative catalytic site are evidenced with an asterisk. Hemolin sequences (with
abbreviation and GenBank™ accession numbers in brackets) are from: Samia cynthia ricini (Sc, BAE07175), Antheraea
pernyi (Ap, AAS99343), Manduca sexta (Ms, AAC46915), Losac (Lo, ABF21073) and H. cecropia (Hc, AAB34817).
At this stage we can only speculate about the mechanism of action of Losac. One possibility is
to evaluate structural features that might contribute to the Losac-induced factor X activation.
Thus, a search for serine protease active-site was undertaken based on the Catalytic Site Atlas
(CSA) program analysis. Three possible catalytic residues, Asp(D)40, His(H)72 and Ser(S)90, were
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located on D1 (Figure 13 and 14A) and could fit to such activity. Theoretical analysis (Figure
13 and 14) and observed results - total inhibition by PMSF as described in [28] - seem to suggest
the presence of a serine protease-like active-site in Losac which would be responsible for the
proteolytic activation of factor X [20, 28, 84]. Some molecular techniques, such as Site-directed
mutagenesis [101], could be applied in an effort to understand the structural requirements for
ligand binding and selectivity and identification of active site residues.
Functionally, hemolins were first associated with the insect immune system because of their
over-expression after bacterial infection [103]. Due to their adhesion properties, some hemolins
have been involved in the cell adhesion mechanisms. In the last two decades independent
studies demonstrated that hemolins are multifunctional molecules involved in a diverse range
Figure 14. Three-dimensional structure model of Losac. (A) Cartoon view of the predicted model of Losac protein
built from the structural coordinates of H. cecropia hemolin (PDB code 1BIH) using Modeller 9v1 [102]. Each domain
(D1-D4) comprises α-helices and 7 strands arranged in 2 antiparallel β-sheets that are linked together by a disulfide
bridge (shown in yellow stick). The residues of the putative catalytic triad predicted in D1 by the program Catalytic Site
Atlas (http://www.ebi.ac.uk/thornton-srv/databases/CSA/) program, are indicated as stick cyan color by the one let‐
ter code followed by the residue number, D40, H72, S90. (B) Electrostatic potential surface of Losac showing inside the
box the conserved phosphate-binding site at the D2-D3 interface domains, exactly as was demonstrated for HcHemo‐
lin [97]. (C) Surface view of Losac model evidencing the conserved adhesive motif KDG (deep blue) and the LPS-bind‐
ing motif RRVT (green) and NRTS (chocolate), which contains the glycosylation site in N265. All the figures were
produced in Pymol v1.5 (http://www.pymol.org/).
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of cell interaction [104-110]. The high identity among Losac and hemolins suggests that Losac
could also assume some of these functions in L. obliqua. The adhesive properties of Losac
probably are relevant to understanding the human umbilical vein endothelial cell responses
observed in previous studies.
4. Biomedical applications
Studies on L. obliqua toxins with a molecular approach have applications beyond the patho‐
physiology and therapeutic perspectives of envenoming. As procoagulant proteins, Lopap and
Losac can be useful as tools for developing clotting assays and diagnostic kits. Exogenous
factor X activators, such as recombinant Losac, has also the potential to be used for detection
of factor X deficiency and lupus anticoagulant [111]. In the case of Lopap, an exogenous
prothrombin activator, two patents were applied to use this compound in diagnostic kits for
detection of dysprothrombinemias using the native form purified from the venom as well as
the recombinant form produced in bacteria. This prothrombin activator has also the potential
to be used in clotting time assays, prothrombin assays, and to monitor patients anticoagulated
with hirudin. A recent study suggests that exogenous procoagulant proteins could also be
considered for therapeutic use to manage bleeding complications caused by anticoagulation
therapy. Treatment with Lopap was able to reduce the bleeding time of rabbits anticoagulated
with low molecular weight heparin, through direct prothrombin activation, bypassing factor
Xa inhibition [112]. Patent information about those applications can be consulted in Table 3.
Modulation of cell responses triggered by Lonomia toxins can have valuable therapeutic and
biotechnological applications. Promoting cell survival can be useful to improve cell culture
technologies and vaccine productions, and for treatment of degenerative diseases. In addition,
the effects of Lopap on extracellular matrix remodeling can be valuable to develop wound
healing formulations and to regeneration issues (Table 3). For this approaches, design and
synthesis of short peptides derived from Lopap amino acid sequence is an interesting task to
minimize toxic and side effects and for production of this molecules for proofs of concepts,
pre-clinical and clinical tests (Table 3). Isolating specific domains and sequences can also help
to understand the multifunctional properties of the studied proteins and direct structure-
function insights.
Unveiling the mechanisms of action and structure-function relationship of these multifunc‐
tional molecules may pointing out these molecules as promising candidates to development
of new therapeutic drugs, reagents in diagnostic kits for coagulation dysfunctions, and
biotechnological applications.
5. Concluding remarks
Nature has been finding ways to gift living beings with functions that are advantageous,
regarding natural selection, mainly by evolutionary process. Among all the lepidopterans of
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medical interest in the world, Lonomia sp. caterpillars (family: Saturniidae) is the only genus
that causes dramatic damages in human blood coagulation [16, 113]. This feature is reflected
in the diversity of toxins produced by the caterpillar and their unusual enzymatic properties.
Application of molecular approaches in the study of L. obliqua toxins has been a valuable
strategy in understanding the biological means of these molecules for the source organism
itself and the dynamic pathways in envenoming syndrome. On the other hand, this approach
reveals these toxins as interesting tools for therapeutic and biotechnological applications. The
best examples are Lopap (a prothromin activator lipocalin) and Losac (the only hemolin with
proteolytic activity). If, in one hand, the molecular basis of target recognition and proteolysis
of factor X and prothrombin by Losac and Lopap, respectively, needs to be further investigated,
on the other hand, efforts need to be focused on understanding the pro-survival activity of
both molecules.
WIPO patent
application
Publication date Patent Institutions involved
WO/2003/070746 08.28.2003 Purification and characterization of a
prothrombin activator from the bristle of
Lonomia obliqua: to be used in diagnosis kits
for detecting plasma prothrombin in
hemorrhagic state patients
Instituto Butantan
(Brazil); Fapesp (Brazil)
and Biolab Sanus
Farmacêutica Ltda
(Brazil)
WO/2006/021062 02.03.2006 Process for obtaining the recombinant
prothrombin activating protease (rLopap) in
monomeric form; the recombinant
prothrombin activating protease (rLopap) as
well as its amino acid sequence; the use of this
protease as a defibrinogenase agent and the
diagnosis kit for dysprothrombinemias
Instituto Butantan
(Brazil); Fapesp (Brazil)
and Biolab Sanus
Farmacêutica Ltda
(Brazil)
WO/2007/028223 03.15.2007 Lopap-based pharmaceutical compositions and
uses thereof: it refers to the use of Lopap as
modulators of cell death and degeneration
caused by wounds, aging and external agents
Instituto Butantan
(Brazil); Fapesp (Brazil)
and Biolab Sanus
Farmacêutica Ltda
(Brazil)
WO/2009093189 07.30.2009 Peptides, compositions, and uses thereof: it
refers to the uses of Lopap-derived peptides for
regenerating tissues and wound repair
Instituto Butantan
(Brazil); Fapesp (Brazil)
and Biolab Sanus
Farmacêutica Ltda
(Brazil)
Table 3. International patents associated to Lopap and peptides derived from its amino acid sequence. Information
was obtained from World Intellectual Property Organization (WIPO).
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Integrating transcriptomic, proteomic and microarray analysis will provide a wealth of
valuable information about venom composition. Molecular cloning and expression of re‐
combinant toxins from L. obliqua opens new perspectives in the identification and characteri‐
zation of macromolecular fine structure of toxins and its implications for toxic activity as well
as new action mechanisms and target cell binding that should be an area of rapid development.
The next several years will likely see some very significant advances in this field and, in the
future, those approaches will permit the identification of molecular mechanisms at a new level.
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